Table 2. FOLFOX treatment, metastasis status and tumour recurrence sites.

Case	Primary site	Histopathological type	Pre-FOLFOX metastatic site	Synchronous/ metachronous	FOLFOX cycles	DFS (days)	Days from end of FOFLOX until recurrence	Post-FOLFOX recurrence site
1	Rectum	Mode	—	—	3	124	6	Liver
2	Colon	Mode	Liver	Synchronous	4	97	−16a	Liver
3	Colon	Mode	Liver	Synchronous	4	116	26	Liver
4	Rectum	Well	Local recurrence	Metachronous	4	469	363	Local recurrence
5	Rectum	Mode	—	—	5	827	603	Lung
6	Colon	Mode	—	—	5	350	244	Lymph node
7	Rectum	Mode	Liver	Synchronous	8	214	1	Lung
			Lung	Synchronous
8	Rectum	Muc	—	—	8	538	318	Lung
9	Colon	Well	—	—	8	1077	903	Liver
10	Colon	Mode	Liver	Synchronous	8	344	120	Lung
			Liver	Synchronous				Lung
			Lung	Synchronous
11	Colon	Muc	Lung	Synchronous	9	721	401	Lung
12	Rectum	Well	Liver	Synchronous	9	109	−88a	Liver
13	Rectum	Mode	Liver	Metachronous	11	328	120	Liver
			Lung	Metachronous
14	Rectum	Mode	Subcutaneous	Metachronous	12	519	156	Lung
15	Colon	Mode	—	—	12	388	176	Local recurrence
16	Rectum	Mode	Liver	Synchronous	12	466	210	Lung
17	Rectum	Well	Lung	Synchronous	12	556	264	Lung
18	Colon	Mode	Liver	Metachronous	12	531	231	Lung
								Lung
19	Rectum	Mode	Liver	Synchronous	12	409	217	Lung
20	Rectum	Mode	—	—	12	455	243	Local recurrence
21	Rectum	Well	Liver	Metachronous	12	346	71	Lung
								Lung

Abbreviations: DFS=disease-free survival; mode=moderately differentiated adenocarcinoma; muc=mucinous adenocarcinoma; well=well-differentiated adenocarcinoma.

^aThe cases that FOLFOX therapies were administered after recurrence.